Maria-Victoria Mateos1, Cyrille Touzeau2, Carolina Schinke3, Monique C. Minnema4, Jesus Berdeja5, Albert Oriol6, Niels WCJ van de Donk7, Paula Rodriguez-Otero8, Elham Askari9, Ajai Chari10, Luciano J. Costa11, Jo Caers12, Leo Rasche13, Amrita Krishnan14, Deeksha Vishwamitra15, Xuewen Ma15, Xiang Qin15, Katharine S. Gries16, Michela Campagna17, Tara Masterson15, Brandi Hilder15, Jaszianne Tolbert15, Thomas Renaud16, Jenna D. Goldberg16, Christoph Heuck15, Jesus San-Miguel18, Philippe Moreau2
1University Hospital of Salamanca / IBSAL / CIC / CIBERONC, 2University Hospital Hotel-Dieu, 3University of Arkansas for Medical Sciences Winthrop P. Rockefeller Institute, 4University Medical Center Utrecht, 5Sarah Cannon Research Institute and Tennessee Oncology, 6Institut Catala d'Oncologia and Institut Josep Carreras. Hospital Germans Trias i Pujol, 7Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 8Clinica Universidad de Navarra, CIMA, CIBERONC, IDISNA, 9Hospital Universitario Fundacion Jimenez Diaz, 10Mount Sinai School of Medicine, 11University of Alabama at Birmingham, 12University of Liege, 13Universitatsklinikum Wurzburg, Medizinische Klinik und Poliklinik II, 14City of Hope Comprehensive Cancer Center, 15Janssen Research & Development, Spring House, 16Janssen Research & Development, Raritan, 17Janssen Research & Development, Madrid, 18Clinica Universidad de Navarra, CCUN, CIMA, CIBERONC, IDISNA
International Journal of Myeloma 13(3): 130-130, 2023.